Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Trop Med Int Health. 2010 May 7;15(7):842–847. doi: 10.1111/j.1365-3156.2010.02540.x

Table 1.

Adjusted hazard ratios (with 95% confidence intervals) for mortality, clinical treatment failure, and combination outcome of the two, according to nevirapine exposure prior to initiation of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy

Crude hazard ratio
(95% CI)		 Adjusted hazard ratio
(95% CI)
Mortality
     No exposure Ref Ref
     Previous NVP exposure: < 6 months 0.90 (0.22 – 3.64) 0.95 (0.23 – 3.88)
     Previous NVP exposure: 6 to 12 months 0.41 (0.06 – 2.93) 0.53 (0.07 – 3.84)
     Previous NVP exposure: > 12 months 0.28 (0.07 – 1.14) 0.33 (0.08 – 1.34)
     Previous NVP exposure: no timing information 0.64 (0.26 – 1.57) 0.58 (0.21 – 1.59)
Clinical treatment failure
     No exposure Ref Ref
     Previous NVP exposure: < 6 months 2.14 (1.36 – 3.38) 1.52 (0.94 – 2.45)
     Previous NVP exposure: 6 to 12 months 1.33 (0.78 – 2.26) 1.06 (0.61 – 1.84)
     Previous NVP exposure: > 12 months 1.12 (0.78 – 1.62) 0.95 (0.65 – 1.40)
     Previous NVP exposure: no timing information 1.58 (1.17 – 2.12) 1.33 (0.96 – 1.82)
Clinical treatment failure or death
     No exposure Ref Ref
     Previous NVP exposure: < 6 months 1.96 (1.26 – 3.06) 1.43 (0.90 – 2.28)
     Previous NVP exposure: 6 to 12 months 1.24 (0.74 – 2.06) 1.05 (0.62 – 1.79)
     Previous NVP exposure: > 12 months 0.98 (0.68 – 1.42) 0.85 (0.59 – 1.25)
     Previous NVP exposure: no timing information 1.46 (1.10 – 1.95) 1.23 (0.90 – 1.68)

All analyses adjusted for age, body mass index, CD4 count, World Health Organization clinical stage, adherence, and nucleotide reverse transcriptase inhibitor backbone. NVP = nevirapine.